The rate of adverse events was similar across the four groups , with serious adverse events occurring in seven ( @ % ) of @ patients in the tofacitinib @ mg group , five ( @ % ) of @ in the tofacitinib @ mg group , seven ( @ % ) of @ in the etanercept group , and two ( @ % ) of @ in the placebo group .